Fig. 1
From: Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
Construction of the recombinant adenovirus ADV4-HPV16/18/58 mE6E7. A The recombinant adenovirus shuttle plasmid ADV4-HPV16/18/58 mE6E7 and the adenovirus backbone plasmid were cotransfected into 293A cells. B CPE phenomenon after 293A cells were infected with different dilutions of viruses. C AD-HPV16/18/58 mE6E7 and AD-NC viruses were transfected into 293A cells. D The protein expression of E6 and E7 in the 293A/AD-HPV16/18/58 mE6E7 cells was detected by western blots. a: anti-E6 protein b: anti-E7 protein, A: 293A/AD-HPV16/18/58 mE6E7 group, B: 293A/AD-NC group, C: 293A group